In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

This was the stock's fifth consecutive day of losses.

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

This was the stock's fourth consecutive day of losses.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,101.15 today based on a ...

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $92.01 which represents a decrease of $-2.10 or -2.23% from the prior close of $94.11. The stock opened at $93.93 and touched a low of ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

Galapagos (GLPG) stock is in focus as the company looks to amend its 10-year deal with Gilead (GILD) as part of plans to create a new listed unit. Read more here.

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

US biopharmaceuticals giant Gilead has thrown its weight behind a potential merger of Ireland’s Poolbeg Pharma and Austria ...